Analyzing MMP2 and MMP9 in Patients with Newly Diagnosed Glioblastoma
Official title: Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.
Run by Assistance Publique Hopitaux De Marseille · NCT03526822 · Data updated 2026-11-12
This study is testing how levels of certain proteins in the blood relate to brain scans and tumor samples in people who have just been diagnosed with glioblastoma, to see how these levels change during treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Drugs / interventions | chemotherapy, bevacizumab |
| Locations | 1 site (Marseille) |
| Status | Recruiting |
| Started | July 2, 2018 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT03526822 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and over with imaging suggestive of glioblastoma who are eligible for surgical excision and subsequent radiotherapy chemotherapy.
✕Probably not a fit
Patients with nonoperable lesions or those who have previously undergone treatment for glioblastoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients with newly diagnosed glioblastoma, the most aggressive primary brain tumor in adults. It aims to correlate plasma levels of matrix metalloproteinases MMP2 and MMP9 with their tissue expression and neuro-imaging features. The study will also analyze changes in these plasma levels during the peri-operative period and after radio-chemotherapy. Blood and tumor samples will be collected for detailed analysis using enzyme-linked immunosorbent assays.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of glioblastoma biology and improve treatment strategies for patients.
How similar studies have gone: While studies have explored MMPs in glioblastoma, this specific correlation with neuro-imaging features is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete) * Candidate for concomitant and adjuvant radiotherapy chemotherapy (Stupp protocol) * Patient having signed an informed consent * Patient having undergone a preoperative MRI Exclusion Criteria: * Existence of a contraindication to the MRI * Nonoperable lesion * History of radiotherapy and / or chemotherapy for this lesion * Scalability of a low grade lesion * Person in emergency situation, a legal person of legal age (guardianship, guardianship or legal guardianship), or unable to express his or her consent * No affiliation to a social security scheme (beneficiary or beneficiary) * Pregnant or lactating woman
Where it's running
-
Assistance Publique Hôpitaux de Marseille
Marseille, France Recruiting
Study contacts
- Study coordinator: Emeline TABOURET, PH
- Email: emeline.tabouret@ap-hm.fr
- Phone: 491385500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
Temozolomide safety and effectiveness in adults with Grade III–IV glioma
This study tests how safe and effective Amitzo temozolomide is in adults with Grade III or IV glioma in Iran, without a control group.
-
Home-based vision training guided by brain imaging
This study tests whether at‑home, image-guided visual training can improve visual field function for adults with stroke-related vision loss.
-
Memantine and raloxifene to protect memory after brain radiation
This study tests whether adding memantine and raloxifene to brain radiation can help adults preserve memory better than radiation alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.